Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Historical Holders from Q4 2017 to Q3 2025

Symbol
APLS on Nasdaq
CUSIP
03753U106
Type / Class
Equity / Common Stock
Shares outstanding
128M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
122M
Holdings value
$2.77B
% of all portfolios
0.003%
Grand Portfolio weight change
0%
Number of holders
269
Number of buys
150
Number of sells
-120
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 10.9% +52.9% $311M $107M 13.8M +52.6% Wellington Management Group LLP Oct 31, 2025
MORGAN STANLEY 7.7% $172M 9.59M Morgan Stanley Dec 31, 2024
Deep Track Capital, LP 5.57% $126M 7M Deep Track Capital, LP May 9, 2025
BlackRock, Inc. 4.5% $101M 5.6M BlackRock, Inc. Mar 31, 2025
EcoR1 Capital, LLC 2.7% $78M 3.45M EcoR1 Capital, LLC Sep 30, 2025

Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 122M $2.77B -$155M $22.63 269
2025 Q2 132M $2.28B +$66.1M $17.31 246
2025 Q1 126M $2.77B -$78.2M $21.87 251
2024 Q4 127M $4.04B +$259M $31.91 257
2024 Q3 117M $3.38B -$74M $28.84 267
2024 Q2 115M $4.43B +$34.6M $38.36 261
2024 Q1 112M $6.58B -$88.5M $58.78 295
2023 Q4 113M $6.74B +$138M $59.86 282
2023 Q3 112M $4.25B -$358M $38.04 253
2023 Q2 106M $9.69B -$323M $91.10 316
2023 Q1 110M $7.27B +$670M $65.96 277
2022 Q4 100M $5.19B +$67M $51.71 241
2022 Q3 97.4M $6.65B +$28.7M $68.30 253
2022 Q2 91.6M $4.14B +$31.6M $45.22 206
2022 Q1 90.9M $4.62B +$520M $50.81 212
2021 Q4 81M $3.83B +$612M $47.28 185
2021 Q3 69.5M $2.29B -$94.6M $32.96 179
2021 Q2 64.6M $4.08B +$13.4M $63.20 204
2021 Q1 63.3M $2.72B +$19.9M $42.91 170
2020 Q4 63.9M $3.65B -$9.78M $57.20 166
2020 Q3 62.1M $1.87B +$24.7M $30.17 145
2020 Q2 61.2M $2B +$198M $32.66 141
2020 Q1 55.3M $1.48B +$295M $26.79 147
2019 Q4 43.9M $1.34B +$85.7M $30.62 137
2019 Q3 40.4M $973M +$46.4M $24.09 129
2019 Q2 40.5M $1.03B +$17.5M $25.34 99
2019 Q1 40.1M $782M +$161M $19.50 92
2018 Q4 32.1M $423M -$27.3M $13.19 95
2018 Q3 29.7M $528M +$9.62M $17.78 79
2018 Q2 29.1M $639M +$266M $22.00 73
2018 Q1 17M $375M +$8.76M $22.11 46
2017 Q4 15.7M $340M +$340M $21.70 46